The SCCS scientific advice on the safety of nanomaterials in cosmetics.


Journal

Regulatory toxicology and pharmacology : RTP
ISSN: 1096-0295
Titre abrégé: Regul Toxicol Pharmacol
Pays: Netherlands
ID NLM: 8214983

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 25 08 2021
accepted: 06 09 2021
pubmed: 25 9 2021
medline: 18 1 2022
entrez: 24 9 2021
Statut: ppublish

Résumé

The Cosmetic Regulation (EC) No 1223/2009 specifically covers the risk of nanomaterials used in cosmetic products. If there are concerns regarding the safety of a nanomaterial, the European Commission refers it to the SCCS for a scientific opinion. The Commission mandated the SCCS to identify the scientific basis for safety concerns that could be used as a basis for identifying and prioritising nanomaterials for safety assessment, and to revisit previous inconclusive SCCS opinions on nanomaterials to identify any concerns for potential risks to the consumer health. The SCCS Scientific Advice identified the key general aspects of nanomaterials that should raise a safety concern for a safety assessor/manager, so that the nanomaterial(s) in question could be subjected to safety assessment to establish safety to the consumer. The Advice also developed a list of the nanomaterials notified to the Commission for use in cosmetics in an order of priority for safety assessment, and revisited three previous inconclusive opinions on nanomaterials to highlight concerns over consumer safety that merited further safety assessment.

Identifiants

pubmed: 34560169
pii: S0273-2300(21)00187-2
doi: 10.1016/j.yrtph.2021.105046
pii:
doi:

Substances chimiques

Cosmetics 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105046

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Ulrike Bernauer (U)

Federal Institute for Risk Assessment (BfR), Berlin, Germany.

Laurent Bodin (L)

Alternative Energies and Atomic Energy Commission (CEA), Saclay, France.

Qasim Chaudhry (Q)

University of Chester, United Kingdom.

Pieter Jan Coenraads (PJ)

University Medical Center Groningen, Groningen, the Netherlands.

Maria Dusinska (M)

Norwegian Institute for Air Research (NILU), Kjeller, Norway.

Eric Gaffet (E)

Institute Jean Lamour (UMR 7198 CNRS Université de Lorraine), Nancy, France.

Eirini Panteri (E)

National and Kapodistrian University of Athens, School of Pharmacy, Division of Pharmaceutical Chemistry, Athens, Greece.

Vera Rogiers (V)

Vrije Universiteit, Brussels, Belgium.

Christophe Rousselle (C)

French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Maisons-Alfort, France.

Maciej Stepnik (M)

Qsar Lab Ltd., Gdańsk, Poland.

Tamara Vanhaecke (T)

Vrije Universiteit, Brussels, Belgium.

Susan Wijnhoven (S)

National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Natalie von Goetz (N)

Federal Office of Public Health (FOPH), Switzerland.

Wim H de Jong (WH)

Formerly Centre for Health Protection, National Institute for Public Health (RIVM), Bilthoven, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH